Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Maze Therapeutics Inc. is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners, indicating a highly decentralized prosecution strategy. The busiest examiner, ROMERO, KRISTEN WANG, is responsible for 1 pending office action. Since there are 4 pending actions and 4 examiners, each examiner is handling exactly 1 matter, ensuring that no single individual has a dominant influence over the pending portfolio.
The use of 4 distinct art units suggests that the company's technological focus within the Biotechnology & Pharmaceuticals area is broad and covers multiple specialized classifications. Each pending action is being reviewed under a different administrative framework, which may lead to varied prosecution timelines or requirements. This distribution across examiners and 4 art units provides the company with a wide range of feedback from the patent office, reducing the risk associated with a single examiner's discretion.
Practitioners should be prepared to navigate different sets of examiner preferences and art unit standards simultaneously. This structure requires a high level of coordination but offers the benefit of multiple independent paths to patent allowance. The 1 to 1 ratio between pending actions and examiners across the entire portfolio reflects a diverse and well-distributed approach to securing intellectual property rights in the pharmaceutical sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §112 only | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROMERO, KRISTEN WANG | 1 | 68.8% | +31.9% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +39.9% |
| WHITEMAN, BRIAN A | 1 | 68.5% | +16.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17796563 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | WHITEMAN, BRIAN A | 58d overdue |
| 18285802 | COMPOSITIONS AND METHODS FOR TREATING TDP-43 PROTEINOPATHY | POLIAKOVA-GEORGAN, EKATERINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17796563 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | WHITEMAN, BRIAN A | 58d overdue |
| 18485224 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | ROMERO, KRISTEN WANG | 15d |
| 18285802 | COMPOSITIONS AND METHODS FOR TREATING TDP-43 PROTEINOPATHY | POLIAKOVA-GEORGAN, EKATERINA | — |
| 18263118 | VECTORS COMPRISING STUFFER POLYNUCLEOTIDE SEQUENCES | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1637 | 1 |
| 1632 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18485224 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | ROMERO, KRISTEN WANG | 1624 | — | Non-Final OA | 15d | Pending | Oct 11, 2023 |
| 18285802 | COMPOSITIONS AND METHODS FOR TREATING TDP-43 PROTEINOPATHY | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §101§102 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18263118 | VECTORS COMPRISING STUFFER POLYNUCLEOTIDE SEQUENCES | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Jul 26, 2023 |
| 17796563 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | WHITEMAN, BRIAN A | 1636 | §101§102§103§112DP | Final Rejection | 58d overdue | Pending | Jul 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial